Feedback

Efficacy and safety of platelet-rich plasma in the treatment of carpal tunnel syndrome: A network meta-analysis of different injection treatments

Affiliation
Department of Orthopaedic Surgery ,Union Hospital ,Tongji Medical College ,Huazhong University of Science and Technology ,Wuhan ,China
Hong, Pan;
Affiliation
Basic Medical School ,Tongji Medical College ,Huazhong University of Science and Technology ,Wuhan ,China
Zheng, Yu;
Affiliation
Department of Orthopaedics and Trauma Surgery ,Karama Medical Center ,Dubai ,United Arab Emirates
Rai, Saroj;
Affiliation
Second Clinical School, Tongji Medical College, Huazhong University of Science and Technology ,Wuhan ,China
Ding, Yuhong;
Affiliation
Basic Medical School ,Tongji Medical College ,Huazhong University of Science and Technology ,Wuhan ,China
Zhou, Yeming;
Affiliation
Department of Endocrinology ,Union Hospital ,Tongji Medical College ,Huazhong University of Science and Technology ,Wuhan ,China
Liu, Ruikang;
Affiliation
Department of Orthopaedic Surgery ,Union Hospital ,Tongji Medical College ,Huazhong University of Science and Technology ,Wuhan ,China
Li, Jin

Purpose: Carpal tunnel syndrome (CTS) is a common form of median nerve compression in the wrist caused by focal peripheral neuropathy. Platelet-rich plasma (PRP) therapy could improve the healing ability by exposing the injured tissues to high concentrations of autologous growth factors. Our study aims to compare all injective treatments for CTS and assess the efficacy and priority of PRP therapy. Methods: We searched Medline, Embase, Web of Science, Cochrane databases, and Clinicaltrial.gov until 17 October 2022. We only included data from randomized controlled trials (RCTs) that evaluated PRP injection therapy or drug injection therapy. The included RCTs measured at least one of the following three outcomes with validated instruments: in the visual analog scale (VAS), symptom severity scale (SSS), and functional status scale (FSS). Results: Overall, 19 studies with 1,066 patients were included in this study. We used the SUCRA rankings to determine the merits of various therapies. In all, 5% dextrose injections were the best treatment strategy for the VAS (MD −1.22, 95% CI −2.66 to 0.23; SUCRA = 79.2%), followed by triamcinolone (high-dose) injections (MD −0.69, 95% CI −2.11 to 0.73; SUCRA = 62.7%) and PRP injections (MD −0.39, 95% CI −1.67 to 0.89; SUCRA = 60.0%). In the SSS, the most effective intervention was hydroxyprogesterone injections (MD −0.62, 95% CI −1.09 to −0.16; SUCRA = 91.0%). The SUCRA ranking of PRP was second only to steroids and estrogen (MD −0.39, 95% CI −0.60 to −0.18; SUCRA = 60.8%). In the FSS, the best regimen strategy was hydroxyprogesterone injections (MD 0.12, 95% CI −0.30 to 0.54; SUCRA = 99.5%), followed by triamcinolone (low-dose) injections (MD −0.02, 95% CI −0.54 to 0.49; SUCRA = 87.4%) and PRP injections (MD −0.26, 95% CI −0.43 to −0.09; SUCRA = 77.1%). Conclusion: PRP is an alternative choice for CTS treatment. PRP injection is second only to steroids and estrogen in the treatment efficacy of CTS, with a wide indication and safe outcome.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Hong, Zheng, Rai, Ding, Zhou, Liu and Li.

Use and reproduction: